Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
MADRID, SPAIN and CAMBRIDGE MA.
• The approval has been granted by the Spanish Medicines Agency
• The study will be done in patients with 3 psychiatric disorders and 2 neurodegenerative disorders
• This is the first Phase IIa study with Vafidemstat (ORY-2001) in the psychiatric field
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the approval by the Spanish Medicines Agency (AEMPS) of a clinical trial authorization (CTA) to carry out a Phase IIa trial with Vafidemstat (ORY-2001) in patients with episodes of aggressiveness.